Overall, the results suggest that Baicalein modulated the CM‐p53‐HDAC‐8 complex via inhibition of HDAC‐8, resulting in an ascendant performance of Baicalein on inv(16) AML. Here, HDAC8 is linked to acute myeloid leukemia.